title: Targeting heart failure with preserved ejection fraction: current status and future prospects.
abstract: Heart failure with preserved ejection fraction (HFpEF) portrays a significant burden in terms of prevalence, morbidity, mortality, and health care costs. There is a lack of consensus on the basic pathophysiology, definition, and therapeutic targets for therapy for this syndrome. To date, there are no approved therapies available for reducing mortality or hospitalization for these patients. Several clinical trials have recently started to try and bridge this major gap. There is an urgent need to focus on drug and device development for HFpEF as well as to understand HFpEF pathophysiology.
authors.affiliation: Department of Cardiology, Allegheny General Hospital, Pittsburgh, PA, USA.
authors.forename: Manreet
authors.initials: M
authors.lastname: Kanwar
authors.affiliation: Department of Cardiology, Allegheny General Hospital, Pittsburgh, PA, USA.
authors.forename: Claire
authors.initials: C
authors.lastname: Walter
authors.affiliation: Department of Cardiology, Allegheny General Hospital, Pittsburgh, PA, USA.
authors.forename: Megan
authors.initials: M
authors.lastname: Clarke
authors.affiliation: Department of Cardiology, Allegheny General Hospital, Pittsburgh, PA, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Patarroyo-Aponte
mesh_terms: D002317:Cardiovascular Agents / Q000627:therapeutic use*; D018450:Disease Progression; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006760:Hospitalization; D006801:Humans; D020127:Recovery of Function; D012307:Risk Factors; D013318:Stroke Volume; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D002317:Cardiovascular Agents
keywords: HFpEF therapies; diastolic dysfunction